Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 5/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 3/20 | 1.00 |
| ▸ | MMP2 | P08253 | 2/20 | 1.00 |
| ▸ | MMP8 | P22894 | 2/20 | 1.00 |
| ▸ | APP | P05067 | 10/20 | 0.82 |
| ▸ | MAPT | P10636 | 9/20 | 0.82 |
| ▸ | BACE1 | P56817 | 5/20 | 0.82 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.82 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.82 |
| ▸ | TSHR | P16473 | 2/20 | 0.82 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.82 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.82 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.82 |
| ▸ | MAOA | P21397 | 2/20 | 0.82 |
| ▸ | MAOB | P27338 | 2/20 | 0.82 |
| ▸ | MMP13 | P45452 | 2/20 | 0.82 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.82 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.82 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.82 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10077702 | 1.00 | MMP9 (1.00) | MMP9NFKB1MMP2MMP8APP | |
| SCHEMBL13125782 | 1.00 | MMP9 (1.00) | MMP9NFKB1MMP2MMP8APP | |
| SCHEMBL16203057 | 1.00 | MMP9 (1.00) | MMP9NFKB1MMP2MMP8APP | |
| SCHEMBL6847537 | 0.91 | MMP9 (0.84) | MMP9NFKB1MMP2MMP8APP | |
| SCHEMBL13453148 | 0.91 | MMP9 (0.84) | MMP9NFKB1MMP2MMP8APP | |
| SCHEMBL26397843 | 0.91 | MMP9 (0.84) | MMP9NFKB1MMP2MMP8APP | |
| SCHEMBL13324431 | 0.91 | NFKB1 (0.83) | MMP9NFKB1MMP2MMP8APP | |
| Curcumin SCHEMBL8336603 | 0.90 | APP (1.00) | MMP9NFKB1MMP2MMP8APP | |
| Curcumin SCHEMBL8440 | 0.90 | APP (1.00) | MMP9NFKB1MMP2MMP8APP | |
| Curcumin SCHEMBL250984 | 0.90 | APP (1.00) | MMP9NFKB1MMP2MMP8APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160060287-A1 | NUCLEOTIDE AND OLIGONUCLEOTIDE PRODRUGS | SPRING BANK PHARMACEUTICALS, INC. | 2016-03-03 | — | — | US | disclosed |
| US-20140323554-A1 | NUCLEOTIDE AND OLIGONUCLEOTIDE PRODRUGS | SPRING BANK PHARMACEUTICALS, INC. (US) | 2014-10-30 | — | — | US | disclosed |
| US-20120264709-A1 | NUCLEOTIDE AND OLIGONUCLEOTIDE PRODRUGS | SPRING BANK PHARMACEUTICALS, INC. (US) | 2012-10-18 | — | — | US | disclosed |
| US-20110146516-A1 | METHOD OF PREPARING LITHOGRAPHIC PRINTING PLATE | FUJIFILM CORPORATION (JP) | 2011-06-23 | — | — | US | disclosed |
| US-20110020757-A1 | METHOD OF PREPARING LITHOGRAPHIC PRINTING PLATE | FUJIFILM CORPORATION (JP) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264709-A1 | NUCLEOTIDE AND OLIGONUCLEOTIDE PRODRUGS | TYMP, PNP, DUT | MMP9 2682/4885NFKB1 599/4885MMP2 3209/4885 |
| US-20160060287-A1 | NUCLEOTIDE AND OLIGONUCLEOTIDE PRODRUGS | TYMP, PNP, DUT | MMP9 2682/4885NFKB1 599/4885MMP2 3209/4885 |
| US-20140323554-A1 | NUCLEOTIDE AND OLIGONUCLEOTIDE PRODRUGS | TYMP, PNP, DUT | MMP9 2682/4885NFKB1 599/4885MMP2 3209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.